Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-05-31

Study Completion Date

2017-01-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Phase II open study, not randomized with a neoadjuvant therapy,combination of Gemcitabine (1,000 mg/m2/week) with Erlotinib (100mg/day) (3 cycles of 4 weeks), followed by gemcitabine (300 mg/m2/week) combined with Erlotinib (100mg/day) and radiotherapy (45 Gy / day fr180 cGy) (5 cycles of 1 week) in patients with resectable pancreatic adenocarcinoma to assess the percentage of R0 resections. They have planned a total of 21 visits.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer

NCT01303029

Metastatic Pancreatic Cancer

COMPLETED PHASE2

Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic Cancer

NCT00191568

Pancreatic Neoplasms

COMPLETED PHASE2

A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer

NCT00336700

Pancreatic Cancer

TERMINATED PHASE2

Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable

NCT01531712

Pancreatic Cancer

TERMINATED PHASE2

Phase II Study of Hypofractionated Radio-chemotherapy With Gemcitabine Plus Oxaliplatin for Unresectable Nonmetastatic Locally Advanced Pancreatic Cancer.

NCT02035072

Unresectable Pancreatic Cancer Nonmetastatic Pancreatic Cancer Locally Advanced Pancreatic Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Adenocarcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Gemcitabine, Erlotinib and radiotherapy

Gemcitabine + Erlotinib follow by Gemcitabine + Erlotinib + radiotherapy

Group Type EXPERIMENTAL

Gemcitabine and Erlotinib

Intervention Type DRUG

Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gemcitabine and Erlotinib

Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Gemcitabine and Tarceva

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Able to sign the inform consent form
* Age between 18-75 years
* Subject has not undergone any chemotherapy or radiotherapy previously
* Functional status o-1 (ECOG scale)
* Patients with a cytologically confirmed diagnosis of pancreatic adenocarcinoma(preferably by EUS)
* bone marrow status: neutrophils ≥ 1,500x10\^9/L; platelets ≥ 100x10\^9/L; hemoglobin ≥ 9g/dL.
* INR ≤ 1.5 and PTT ≤ 1.5 x upper range of normal.
* Bilirubin ≤ 5 mg/dL
* Albumin\> 34 g/L
* Renal function: creatinine ≤ 1.5 mg/dL and creatinine clearance\> 50ml/min

Exclusion Criteria

* patients treated with any of the study's drugs
* patients who has develop other primary tumors in 5 years prior to the inclusion at the clinical trial, except for cervix carcinoma in situ or basal cell skin cancer which have been treated properly.
* significant clinical cardiovascular disease: stroke (≤ 6 months before the study inclusion), heart attack (≤ 6 months before inclusion), unstable ango pectoris, congestive heart failure second grade or higher of the New York Heart Association (NYHA) or serious cardiac arrhythmia requiring medication, uncontrolled hypertension
* Total o partial bowel obstruction
* Chronic diarrhea
* Current treatment with another investigational drug or participation in another clinical trial within 30 days prior to inclusion.
* Known hypersensitivity to any of the study drugs or their components
* Currently o recent therapeutic treatment (opposite to prophylactic) with oral or parenteral anticoagulants (full dose) or thrombolytic agents. Patients who receive (or are candidates to receive) anticoagulants for prophylaxis of cardiovascular risk, should continue (or begin) treatment at baseline
* Thromboembolic event history or bleeding in the 6 months prior to treatment.
* Evidence of bleeding diathesis or coagulopathy.
* Serious problems in wounds healing, ulcers or bone fractures.
* Major surgery, open biopsy or significant traumatic injury 28 days before treatment.
* Any other disease, metabolic disorder, physical examination findings or clinical laboratory that provides reasonable evidence for suspecting a disease or condition for which it is contraindicated or patient an experimental drug at high risk of experiencing complications related to treatment .
* Patients undergoing with organ allografts requiring immunosuppressive treatment.
* Pregnant or breastfeeding woman. It requires a negative pregnancy test (serum or urine) within 7 days before previous to treatment.
* Men and women of childbearing potential (including women who have had their last menstrual period in less than 2 years) not using effective contraception precautions
* Positive HIV status
* Addiction to alcohol or other drugs
* Known liver cirrhosis

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No